These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 7605161)

  • 21. Summaries for patients. Treatment of histoplasmosis in patients with HIV infection.
    Ann Intern Med; 2002 Jul; 137(2):I54. PubMed ID: 12118987
    [No Abstract]   [Full Text] [Related]  

  • 22. Long-term amphotericin B therapy for disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome (AIDS).
    McKinsey DS; Gupta MR; Riddler SA; Driks MR; Smith DL; Kurtin PJ
    Ann Intern Med; 1989 Oct; 111(8):655-9. PubMed ID: 2802421
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial.
    Davidson RN; Di Martino L; Gradoni L; Giacchino R; Russo R; Gaeta GB; Pempinello R; Scott S; Raimondi F; Cascio A
    Q J Med; 1994 Feb; 87(2):75-81. PubMed ID: 8153291
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia.
    Noel GJ
    J Pediatr; 1999 Sep; 135(3):399. PubMed ID: 10523149
    [No Abstract]   [Full Text] [Related]  

  • 25. Successful stepdown treatment of pulmonary histoplasmosis with thrice-weekly liposomal amphotericin B in a hospital-associated, outpatient infusion centre: A case report.
    Lewis PO; Khan I; Patel P
    J Clin Pharm Ther; 2018 Apr; 43(2):269-272. PubMed ID: 28806478
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Liposomal amphotericin B for the treatment of visceral leishmaniasis.
    Bern C; Adler-Moore J; Berenguer J; Boelaert M; den Boer M; Davidson RN; Figueras C; Gradoni L; Kafetzis DA; Ritmeijer K; Rosenthal E; Royce C; Russo R; Sundar S; Alvar J
    Clin Infect Dis; 2006 Oct; 43(7):917-24. PubMed ID: 16941377
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Liposomal amphotericin B for the treatment of severe fungal infection.
    Michaud D
    Dynamics; 2001; 12(1):17-21. PubMed ID: 11982230
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Amphotericin B. Lipid complex versus liposomes. Which, why, when?].
    Pahissa A
    Enferm Infecc Microbiol Clin; 1997 Jan; 15(1):1-3. PubMed ID: 9147499
    [No Abstract]   [Full Text] [Related]  

  • 29. Liposomal amphotericin B for fever and neutropenia.
    Prentice HG; Kibbler CC
    N Engl J Med; 1999 Oct; 341(15):1152-3; author reply 1154-5. PubMed ID: 10515751
    [No Abstract]   [Full Text] [Related]  

  • 30. Reader clarifies the use of amphotericin B.
    Madej T
    Oncol Nurs Forum; 1998 May; 25(4):653. PubMed ID: 9599340
    [No Abstract]   [Full Text] [Related]  

  • 31. Disseminated histoplasmosis--prognosis and treatment.
    Kampmeier RH
    South Med J; 1971 Dec; 64(12):1541. PubMed ID: 5131340
    [No Abstract]   [Full Text] [Related]  

  • 32. Successful treatment of cryptococcal meningitis with liposomal amphotericin B (L-AMP-LRC-1) intolerant to conventional amphotericin B.
    Kirodian BG; Virani AR; Kshirsagar NA
    J Assoc Physicians India; 2002 Apr; 50():601-2. PubMed ID: 12164423
    [No Abstract]   [Full Text] [Related]  

  • 33. [Method for intramuscular administration of amphotericin B in treatment of patients with visceral mycoses].
    Arievich AM; Minsker OB; Pinzur GS
    Antibiotiki; 1971 Sep; 16(9):858-60. PubMed ID: 5139459
    [No Abstract]   [Full Text] [Related]  

  • 34. Histoplasmosis: long term remission following treatment with low dose amphotericin-B.
    Eravelly J; Ramanathan K; Eapen JS
    Med J Malaysia; 1975 Sep; 30(1):59-62. PubMed ID: 1236666
    [No Abstract]   [Full Text] [Related]  

  • 35. [Efficacy of liposomal amphotericin in the treatment of cryptococcal meningitis in a cirrhotic patient with intolerance to conventional amphotericin].
    Fortún J; Pereira E; Martín de Argila C; Gil-Grandes L
    Med Clin (Barc); 1993 Jun; 101(5):198-9. PubMed ID: 8332016
    [No Abstract]   [Full Text] [Related]  

  • 36. The novel lipid delivery system of amphotericin B: drug profile and relevance to clinical practice.
    Rust DM; Jameson G
    Oncol Nurs Forum; 1998; 25(1):35-48. PubMed ID: 9460772
    [TBL] [Abstract][Full Text] [Related]  

  • 37. U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis.
    Meyerhoff A
    Clin Infect Dis; 1999 Jan; 28(1):42-8; discussion 49-51. PubMed ID: 10028069
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nosocomial amphotericin B. Current status.
    Sarosi GA
    Arch Intern Med; 1989 Nov; 149(11):2402-3. PubMed ID: 2818101
    [No Abstract]   [Full Text] [Related]  

  • 39. Systemic antifungal drugs.
    Med Lett Drugs Ther; 1997 Sep; 39(1009):86-8. PubMed ID: 9305292
    [No Abstract]   [Full Text] [Related]  

  • 40. [Neonatal candidiasis and liposomal amphotericin B treatment: our experience].
    Carrasco Sánchez P; Castillo Montero ML; Bejarano Palma A; López Sanz A; Santano Gallinato M; Sáenz Reguera C; Durán de Vargas L; González-Meneses A
    An Esp Pediatr; 1999 Sep; 51(3):273-80. PubMed ID: 10575751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.